

Press Release



ASKA Pharmaceutical Holdings Selected for Inclusion in FTSE Blossom Japan Index

TOKYO, July 3, 2023 - ASKA Pharmaceutical Holdings Co., Ltd. (Head Office: Minato-ku, Tokyo / President, Representative Director: Takashi Yamaguchi, hereinafter “ASKA”) is pleased to announce that ASKA has been selected for inclusion in the FTSE Blossom Japan Index.

Created by the global index and data provider FTSE Russell, the FTSE Blossom Japan Index is designed as an industry-neutral benchmark that reflects the performance of companies demonstrating strong Environmental, Social, and Governance (ESG) practices in Japan.

FTSE Russell evaluations are based on performance in areas such as Corporate Governance, Health & Safety, Anti-Corruption, and Climate Change. Businesses included in the FTSE Blossom Japan Index meets a variety of environmental, social, and governance criteria.” Moreover, ASKA has been selected as a constituent of the FTSE Blossom Japan Sector Relative Index, a new ESG investment index by FTSE Russell, adopted by the GPIF in March 2022 for two consecutive years since its inception.

In April 2021, in conjunction with its transition to a holding company structure, ASKA established the ESG Committee, which is working on a total of 17 materialities (the most important issues), including “contribution to women’s health” and “contribution to animal health.” In April 2023, ASKA appointed a board member in charge of sustainability and established a dedicated department to accelerate our efforts to date further. ASKA will continue to work proactively to resolve these issues in the future to achieve sustainable growth and enhance its corporate value over the medium to long term.

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.
Corporate Planning Department
Tel: +81-3-5484-8366
Email: kouhou@aska-pharma.co.jp